BaiLi Tianheng BL-B01D1 is planned to be included in groundbreaking therapeutic varieties.

The official website of the CDE shows that Sichuan Baili Pharmaceutical Co., Ltd.'s Class 1 new drug injectable BL-B01D1 is intended to be included in breakthrough therapeutic varieties for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients. BL-B01D1 is the world's first global Phase 3 clinical trial of EGFR/HER3 dual antibody ADC independently developed by Baili Tianheng.